Crescendo Bioscience

Crescendo Bioscience, with the slogan "Empowering rheumatologists with precise diagnostic tools for autoimmune and inflammatory disease management," was founded in 2002 in South San Francisco, California. The company, originally known as Riley Genomics, Inc., focuses on creating diagnostic, prognostic, staging, therapy selection, and monitoring solutions for physicians dealing with autoimmune and inflammatory conditions. In January 2013, Crescendo Bioscience secured a noteworthy $28.00M Series D investment from a group of prominent investors including Kleiner Perkins, Mohr Davidow Ventures, Skyline Ventures, Safeguard Scientifics, and Aeris Capital. Crescendo Bioscience’s mission to provide rheumatologists with precise diagnostic tools for managing autoimmune and inflammatory diseases aligns with the increasing demand for innovative healthcare solutions. The company's focus on biotechnology and healthcare industries positions it to capitalize on the growing need for advanced diagnostic and therapeutic solutions in the medical field. With its strong investor backing, the company is well-positioned to further develop and commercialize its diagnostic tools, potentially driving impactful advancements in autoimmune and inflammatory disease management.